Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

131.75 -0.41 (-0.31%)

Streaming Delayed Price Updated: 11:10 AM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

What to Expect from Novartis's Earnings ↗

October 27, 2025

Via Benzinga

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

October 27, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END

Via FinancialNewsMedia

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal ↗

October 27, 2025

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Via Benzinga

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today ↗

October 27, 2025

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Via Stocktwits

Stock Market Today: Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus ↗

October 27, 2025

U.S. stock futures rose on Monday following Friday’s positive moves. Futures of major benchmark indices were higher.

Via Benzinga

Topics Stocks

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket ↗

October 27, 2025

Via Benzinga

Inhibrx Stock Soars on Breakthrough Chondrosarcoma Trial Results: A New Dawn for Rare Cancer Treatment

October 24, 2025

San Diego, CA – October 24, 2025 – Inhibrx (NASDAQ: INBX) shares have surged dramatically, skyrocketing over 70% in pre-market and after-hours trading, following the announcement of overwhelmingly...

Via MarketMinute

Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock ↗

October 24, 2025

Kratos secured a $68.3 million deal and a contract through the Defense Department's Industrial Base Analysis and Sustainment Program.

Via Benzinga

AI Revolutionizes Drug Discovery and Personalized Medicine: A New Era of Healthcare

October 22, 2025

The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain ↗

October 22, 2025

Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing significant sustained remission.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS): A Pillar of Dividend Reliability and Financial Health ↗

October 21, 2025

Novartis (NVS) offers a strong 3.35% dividend yield with a history of steady growth, backed by robust profitability and sound financial health for reliable income.

Via Chartmill

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial ↗

October 17, 2025

Novartis' five-year NATALEE trial shows Kisqali plus endocrine therapy reduces recurrence risk and improves breast cancer survival.

Via Benzinga

Eli Lilly Makes A Bold Claim For Its Biggest Cancer Drug ↗

October 17, 2025

Eli Lilly said Friday a combo using Verzenio cut the risk of death by nearly 16% over two years for breast cancer patients.

Via Investor's Business Daily

AI: The Medical Maverick – Navigating Hype and Hope in Healthcare’s Digital Revolution

October 16, 2025

Artificial intelligence (AI) stands at the precipice of a profound transformation in healthcare, promising a future where diagnostics are sharper, treatments are more personalized, and patient care is...

Via TokenRing AI

Topics Artificial Intelligence

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗

October 16, 2025

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors ↗

October 16, 2025

Novartis (NVS) is a financially sound pharma leader trading at an attractive valuation with strong profitability and steady growth.

Via Chartmill

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗

October 14, 2025

Telitacicept showed strong efficacy and safety in a 48-week Phase 3 trial for Sjögren's disease, meeting all primary and secondary endpoints.

Via Benzinga

Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results

October 13, 2025

Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from...

Via MarketMinute

Topics Economy Supply Chain

Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest? ↗

October 13, 2025

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

Via The Motley Fool

Topics ETFs Government World Trade

JPMorgan Elevates Incyte Price Target Amidst Robust Pipeline and Commercial Success, Yet Maintains Cautious "Neutral" Stance

October 10, 2025

JPMorgan Chase & Co. (NYSE: JPM) has recently recalibrated its outlook on the biopharmaceutical giant Incyte Corporation (NASDAQ: INCY), with a notable upward revision of its price target for the...

Via MarketMinute

Topics Economy Intellectual Property

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Cullen Capital Dumps 40% of BCE Holdings ↗

October 07, 2025

Via The Motley Fool

AI Unlocks Secrets of Intrinsically Disordered Proteins: A Paradigm Shift in Biomedical Design

October 06, 2025

A groundbreaking advancement in artificial intelligence has opened new frontiers in understanding and designing intrinsically disordered proteins (IDPs), a class of biomolecules previously considered...

Via TokenRing AI

Topics Artificial Intelligence Derivatives

European Markets Soar: Healthcare and Mining Lead the Charge Amidst Dovish Fed and Robust Fundamentals

October 04, 2025

European financial markets are currently experiencing a period of remarkable strength, with major indices reaching or nearing all-time highs in early October 2025. This significant rally is largely...

Via MarketMinute

Topics Artificial Intelligence Economy Electric Vehicles

2 Surefire Dividend Stocks to Buy for the Long Haul ↗

October 04, 2025

Both have crushed the market in 2025.

Via The Motley Fool

Topics Economy Government Intellectual Property

Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures

October 02, 2025

A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human...

Via MarketMinute

Topics Artificial Intelligence Derivatives

Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings

October 02, 2025

Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to...

Via MarketMinute

Topics Economy Intellectual Property Stocks

Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design

October 02, 2025

London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...

Via TokenRing AI

Topics Artificial Intelligence

AI Revolutionizes Pharma: Market Soars Towards $65 Billion by 2033, Promising a New Era of Medicine

October 02, 2025

The pharmaceutical industry is on the cusp of a profound transformation, driven by the accelerating integration of Artificial Intelligence (AI). Projections indicate that the global AI in...

Via TokenRing AI

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 5 6 7 8 9

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.